Danish Pharmacovigilance Update 28 November 2013
03 February 2014
In this issue of Danish Pharmacovigilance Update:
News from the EU
- Acipimox (Olbetam®) should only be used to lower triglycerides when other treatments of dyslipidaemia are not sufficient
- Risk of blood clots from the use of the cancer medicine ponatinib (Iclusig®)
- All patients should be screened for hepatitis B virus (HBV) before starting treatment with rituximab (Mabthera®)
- Preparation error resulting in overdose of cabazitaxel (Jevtana)
News from the Danish Health and Medicines Authority
- Ciprofloxacin and the risk of tendon disorders
- Decrease in the use of medicines for the treatment of anogenital warts in adolescents under the age of 20
- Bisphosphonates/denosumab and the risk of osteonecrosis of the jaw
- The tugboats of preventive health – an article from the Danish weekly newspaper Weekendavisen
Short news
- Batches of the NovoMix®30 FlexPen® recalled
- Reporting of adverse reactions to the Danish Health and Medicines Authority
- Danish Pharmacovigilance Update celebrates its 4th anniversary